Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 21, 2022 - Issue 4
Submit an article Journal homepage
1,192
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Resistance to hedgehog inhibitors in basal cell carcinoma: strategies to adopt

Alessia VillaniDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence[email protected]
View further author information
,
Gabriella FabbrociniDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
,
Francesc Di VicoDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
,
Francesca NastroDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
&
Massimiliano ScalvenziDermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyView further author information
Pages 583-584 | Received 13 Dec 2021, Accepted 01 Feb 2022, Published online: 08 Feb 2022

References

  • Villani A, Megna M, Fabbrocini G, et al. Efficacy of vismodegib after its withdrawal and patients’ health-related quality of life using the dermatology life quality index (DLQI). Dermatol Ther (Heidelb). 2019 Dec;9(4):719–724. Epub 2019 Sep 10.
  • Russell-Goldman E, MacConaill L, Hanna J. Hedgehog Pathway Alterations downstream of patched-1 are common in infundibulocystic basal cell carcinoma. Am J Dermatopathol. 2021 Apr 1;43(4):266–272.
  • Villani A, Cinelli E, Fabbrocini G, et al. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits. Expert Opin Drug Saf. 2020 Dec 01;19(12):1585–1594.
  • Ogden T, Higgins S, Elbaum D, et al. The relevance of a suppressor of fused (SUFU) mutation in the diagnosis and treatment of Gorlin syndrome. JAAD Case Rep. 2018 Mar 01;4(2):196–199.
  • Harrison Zhu BSA, Daniel J, Lewis MD. Genetic alterations conferring resistance to hedgehog inhibitors in basal cell carcinoma.
  • Villani A, Fabbrocini G, Costa C, et al. Expert opinion on sonidegib efficacy, safety and tolerability. Expert Opin Drug Saf. 2021 Aug 03;20(8):877–882.
  • Doan HQ, Chen L, Nawas Z, et al. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Oncotarget. 2021 Sep 28;12(20):2089–2100.
  • Franco AI, Eastwick G, Farah R, et al. Upfront radiotherapy with concurrent and adjuvant vismodegib is effective and well-tolerated in a patient with advanced, multifocal basal cell carcinoma. Case Rep Dermatol Med. 2018 Feb 21;2018:2354146. PMID: 29682362; PMCID: PMC5841099.
  • Scalvenzi M, Villani A, Mazzella C, et al. Vismodegib treatment in a HIV positive patient on antiretroviral therapy. Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):758–760.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.